Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Pharma
As questions swirl, Alnylam eyes ATTR market leadership by 2030
Alnylam aspires for Amvuttra to become the revenue leader in an expansive ATTR-CM market of more than 75,000 U.S.-treated patients by 2030.
Angus Liu
Mar 26, 2026 2:08pm
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
Feb 6, 2026 9:48am
Alnylam drafts $250M upgrade to its Mass. drug factory
Dec 17, 2025 10:12am
Alnylam's ATTR-CM launch blows past estimates again
Oct 30, 2025 8:00am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
Novartis, Sarepta tipped to drive genomic therapy sales boom
May 15, 2025 12:18pm
